TERT promoter mutations in cancer development

Current Opinion in Genetics and Development

Volumn 24, Issue 1, 2014, Pages 30-37

  Heidenreich, Barbara ^a   Rachakonda, P Sivaramakrishna ^a   Hemminki, Kari ^a,b   Kumar, Rajiv ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; TELOMERASE REVERSE TRANSCRIPTASE;

BASAL CELL CARCINOMA; BLADDER CANCER; CARCINOGENESIS; ENDOMETRIUM CANCER; FIBROSARCOMA; FIBROXANTHOMA; GENE CONTROL; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE STRUCTURE; GENETIC SCREENING; GLIOMA; HUMAN; LIVER CANCER; MEDULLOBLASTOMA; MYXOSARCOMA; NEUROBLASTOMA; NEUROEPITHELIOMA; ONCOGENE; OSTEOSARCOMA; OVARY CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SARCOMA; SOLITARY FIBROUS TUMOR; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; TERT GENE; THYROID CANCER; TRANSCRIPTION REGULATION;

ANIMALS; HUMANS; MUTATION; NEOPLASMS; NUCLEIC ACID CONFORMATION; PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 84890636883     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2013.11.005     Document Type: Review

References (107)

1. Lu Y., Wei B., Zhang T., Chen Z., Ye J. How will telomeric complex be further contributed to our longevity? The potential novel biomarkers of telomere complex counteracting both aging and cancer. Protein Cell 2013, 4:573-581.
2. de Lange T. How telomeres solve the end-protection problem. Science 2009, 326:948-952.
3. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965, 37:614-636.
4. Cong Y.S., Wright W.E., Shay J.W. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002, 66:407-425.
5. Nandakumar J., Cech T.R. Finding the end: recruitment of telomerase to telomeres. Nat Rev Mol Cell Biol 2013, 14:69-82.
6. Masutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., Brooks M.W., Kaneko S., Murakami S., DeCaprio J.A., et al. Telomerase maintains telomere structure in normal human cells. Cell 2003, 114:241-253.
7. Marion R.M., Blasco M.A. Telomere rejuvenation during nuclear reprogramming. Curr Opin Genet Dev 2010, 20:190-196.
8. Lopez-Otin C., Blasco M.A., Partridge L., Serrano M., Kroemer G. The hallmarks of aging. Cell 2013, 153:1194-1217.
9. Bernardes de Jesus B., Blasco M.A. Telomerase at the intersection of cancer and aging. Trends Genet 2013, 29:513-520.
10. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
11. Low K.C., Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 2013, 38:426-434.
12. Heaphy C.M., Subhawong A.P., Hong S.M., Goggins M.G., Montgomery E.A., Gabrielson E., Netto G.J., Epstein J.I., Lotan T.L., Westra W.H., et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011, 179:1608-1615.
13. Lovejoy C.A., Li W., Reisenweber S., Thongthip S., Bruno J., de Lange T., De S., Petrini J.H., Sung P.A., Jasin M., et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012, 8:e1002772.
14. Cesare A.J., Reddel R.R. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010, 11:319-330.
15. Heaphy C.M., de Wilde R.F., Jiao Y., Klein A.P., Edil B.H., Shi C., Bettegowda C., Rodriguez F.J., Eberhart C.G., Hebbar S., et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333:425.
16. Podlevsky J.D., Chen J.J. It all comes together at the ends: telomerase structure, function, and biogenesis. Mutat Res 2012, 730:3-11.
17. Weinrich S.L., Pruzan R., Ma L., Ouellette M., Tesmer V.M., Holt S.E., Bodnar A.G., Lichtsteiner S., Kim N.W., Trager J.B., et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997, 17:498-502.
18. Masutomi K., Kaneko S., Hayashi N., Yamashita T., Shirota Y., Kobayashi K., Murakami S. Telomerase activity reconstituted in vitro with purified human telomerase reverse transcriptase and human telomerase RNA component. J Biol Chem 2000, 275:22568-22573.
19. Lewis K.A., Wuttke D.S. Telomerase and telomere-associated proteins: structural insights into mechanism and evolution. Structure 2012, 20:28-39.
20. Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M., Veenstra T.D., Terns M.P., Artandi S.E. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009, 323:644-648.
21. Egan E.D., Collins K. Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled in vivo. Mol Cell Biol 2010, 30:2775-2786.
22. Collins K. The biogenesis and regulation of telomerase holoenzymes. Nat Rev Mol Cell Biol 2006, 7:484-494.
23. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791.
24. Shay J.W., Zou Y., Hiyama E., Wright W.E. Telomerase and cancer. Hum Mol Genet 2001, 10:677-685.
25. Venteicher A.S., Artandi S.E. TCAB1: driving telomerase to Cajal bodies. Cell Cycle 2009, 8:1329-1331.
26. Fu D., Collins K. Distinct biogenesis pathways for human telomerase RNA and H/ACA small nucleolar RNAs. Mol Cell 2003, 11:1361-1372.
27. Cristofari G., Sikora K., Lingner J. Telomerase unplugged. ACS Chem Biol 2007, 2:155-158.
28. Shay J.W., Wright W.E. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006, 5:577-584.
29. Hiyama E., Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007, 96:1020-1024.
30. Wright W.E., Piatyszek M.A., Rainey W.E., Byrd W., Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996, 18:173-179.
31. Xu L., Li S., Stohr B.A. The role of telomere biology in cancer. Annu Rev Pathol 2013, 8:49-78.
32. Kolquist K.A., Ellisen L.W., Counter C.M., Meyerson M., Tan L.K., Weinberg R.A., Haber D.A., Gerald W.L. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998, 19:182-186.
33. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen R.L., Knoll J.H., Meyerson M., Weinberg R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999, 5:1164-1170.
34. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
35. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998, 396:84-88.
36. Hahn W.C., Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med 2001, 33:123-129.
37. Zhu J., Zhao Y., Wang S. Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell 2010, 1:22-32.
38. Armanios M., Greider C.W. Telomerase and cancer stem cells. Cold Spring Harb Symp Quant Biol 2005, 70:205-208.
39. Cong Y.S., Wen J., Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999, 8:137-142.
40. Poole J.C., Andrews L.G., Tollefsbol T.O. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001, 269:1-12.
41. Horikawa I., Cable P.L., Afshari C., Barrett J.C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999, 59:826-830.
42. Gladych M., Wojtyla A., Rubis B. Human telomerase expression regulation. Biochem Cell Biol 2011, 89:359-376.
43. Wojtyla A., Gladych M., Rubis B. Human telomerase activity regulation. Mol Biol Rep 2011, 38:3339-3349.
44. Xu D., Dwyer J., Li H., Duan W., Liu J.P. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 2008, 283:23567-23580.
45. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 2008, 99:1528-1538.
46. Hashimoto M., Kyo S., Hua X., Tahara H., Nakajima M., Takakura M., Sakaguchi J., Maida Y., Nakamura M., Ikoma T., et al. Role of menin in the regulation of telomerase activity in normal and cancer cells. Int J Oncol 2008, 33:333-340.
47. Akutagawa O., Nishi H., Kyo S., Terauchi F., Yamazawa K., Higuma C., Inoue M., Isaka K. Early growth response-1 mediates downregulation of telomerase in cervical cancer. Cancer Sci 2008, 99:1401-1406.
48. Cerezo A., Kalthoff H., Schuermann M., Schafer B., Boukamp P. Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. J Cell Sci 2002, 115:1305-1312.
49. Li H., Lee T.H., Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem 2002, 277:20965-20973.
50. Kanaya T., Kyo S., Hamada K., Takakura M., Kitagawa Y., Harada H., Inoue M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000, 6:1239-1247.
51. Dwyer J.M., Liu J.P. Ets2 transcription factor, telomerase activity and breast cancer. Clin Exp Pharmacol Physiol 2010, 37:83-87.
52. Goueli B.S., Janknecht R. Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 2004, 24:25-35.
53. Maida Y., Kyo S., Kanaya T., Wang Z., Yatabe N., Tanaka M., Nakamura M., Ohmichi M., Gotoh N., Murakami S., et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 2002, 21:4071-4079.
54. Lin S.Y., Elledge S.J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003, 113:881-889.
55. Li A.Y., Lin H.H., Kuo C.Y., Shih H.M., Wang C.C., Yen Y., Ann D.K. High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Mol Cell Biol 2011, 31:2605-2617.
56. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
57. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
58. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
59. Dhomen N., Reis-Filho J.S., da Rocha Dias S., Hayward R., Savage K., Delmas V., Larue L., Pritchard C., Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
60. Michaloglou C., Vredeveld L.C., Mooi W.J., Peeper D.S. BRAF(E600) in benign and malignant human tumours. Oncogene 2008, 27:877-895.
61. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
62. Kumar R., Angelini S., Snellman E., Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004, 122:342-348.
63. Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A., Friedman A.H., Friedman H., Gallia G.L., Giovanella B.C., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013, 110:6021-6026.
64. Liu X., Wu G., Shan Y., Hartmann C., von Deimling A., Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013, 12:1637-1638.
65. Hurst C.D., Platt F.M., Knowles M.A. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2013, 10.1016/j.eururo.2013.08.057.
66. Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M., van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2013, 10.1016/j.eururo.2013.08.052.
67. Vinagre J., Almeida A., Populo H., Batista R., Lyra J., Pinto V., Coelho R., Celestino R., Prazeres H., Lima L., et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013, 4:2185.
68. Griewank K.G., Murali R., Schilling B., Scholz S., Sucker A., Song M., Susskind D., Grabellus F., Zimmer L., Hillen U., et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 2013, 109:497-501.
69. Arita H., Narita Y., Fukushima S., Tateishi K., Matsushita Y., Yoshida A., Miyakita Y., Ohno M., Collins V.P., Kawahara N., et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013, 126:267-276.
70. Liu X., Bishop J., Shan Y., Pai S., Liu D., Murugan A.K., Sun H., El-Naggar A.K., Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013, 20:603-610.
71. Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013, 98:E1562-E1566.
72. Tallet A., Nault J.C., Renier A., Hysi I., Galateau-Salle F., Cazes A., Copin M.C., Hofman P., Andujar P., Le Pimpec-Barthes F., et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2013, 10.1038/onc.2013.351.
73. Nonoguchi N., Ohta T., Oh J.E., Kim Y.H., Kleihues P., Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013, 126:931-937.
74. Nault J.C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Rossi J.Z. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013, 4:2218.
75. Griewank K.G., Schilling B., Murali R., Bielefeld N., Schwamborn M., Sucker A., Zimmer L., Hillen U., Schaller J., Brenn T., et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol 2013, 10.1038/modpathol.2013.168.
76. Scott G.A., Laughlin T.S., Rothberg P.G. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol 2013, 10.1038/modpathol.2013.167.
77. Zhao Y., Gao Y., Chen Z., Hu X., Zhou F., He J. Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. Int J Cancer 2013, 134:493-494.
78. Roberts S.A., Lawrence M.S., Klimczak L.J., Grimm S.A., Fargo D., Stojanov P., Kiezun A., Kryukov G.V., Carter S.L., Saksena G., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013, 45:970-976.
79. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Borresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
80. Rachakonda P.S., Hosen I., de Verdier P.J., Fallah M., Heidenreich B., Ryk C., Wiklund N.P., Steineck G., Schadendorf D., Hemminki K., et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 2013, 110:17426-17431.
81. Ding Z., Wu C.J., Jaskelioff M., Ivanova E., Kost-Alimova M., Protopopov A., Chu G.C., Wang G., Lu X., Labrot E.S., et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012, 148:896-907.
82. Rao V.N., Reddy E.S. elk-1 proteins interact with MAP kinases. Oncogene 1994, 9:1855-1860.
83. Kar A., Gutierrez-Hartmann A. Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol 2013, 48:522-543.
84. Buchwalter G., Gross C., Wasylyk B. Ets ternary complex transcription factors. Gene 2004, 324:1-14.
85. Uhlen M., Oksvold P., Fagerberg L., Lundberg E., Jonasson K., Forsberg M., Zwahlen M., Kampf C., Wester K., Hober S., et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010, 28:1248-1250.
86. Jane-Valbuena J., Widlund H.R., Perner S., Johnson L.A., Dibner A.C., Lin W.M., Baker A.C., Nazarian R.M., Vijayendran K.G., Sellers W.R., et al. An oncogenic role for ETV1 in melanoma. Cancer Res 2010, 70:2075-2084.
87. Stewart S.A., Hahn W.C., O'Connor B.F., Banner E.N., Lundberg A.S., Modha P., Mizuno H., Brooks M.W., Fleming M., Zimonjic D.B., et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002, 99:12606-12611.
88. Blasco M.A. Telomerase beyond telomeres. Nat Rev Cancer 2002, 2:627-633.
89. Calado R.T., Chen J. Telomerase: not just for the elongation of telomeres. Bioessays 2006, 28:109-112.
90. Parkinson E.K., Fitchett C., Cereser B. Dissecting the non-canonical functions of telomerase. Cytogenet Genome Res 2008, 122:273-280.
91. Martinez P., Blasco M.A. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011, 11:161-176.
92. Mukherjee S., Firpo E.J., Wang Y., Roberts J.M. Separation of telomerase functions by reverse genetics. Proc Natl Acad Sci U S A 2011, 108:E1363-E1371.
93. Ghosh A., Saginc G., Leow S.C., Khattar E., Shin E.M., Yan T.D., Wong M., Zhang Z., Li G., Sung W.K., et al. Telomerase directly regulates NF-kappaB-dependent transcription. Nat Cell Biol 2012, 14:1270-1281.
94. Beck S., Jin X., Sohn Y.W., Kim J.K., Kim S.H., Yin J., Pian X., Kim S.C., Nam D.H., Choi Y.J., et al. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells 2011, 31:9-15.
95. Xie L., Gazin C., Park S.M., Zhu L.J., Debily M.A., Kittler E.L., Zapp M.L., Lapointe D., Gobeil S., Virbasius C.M., et al. A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. PLoS Genet 2012, 8:e1003151.
96. Del Bufalo D., Rizzo A., Trisciuoglio D., Cardinali G., Torrisi M.R., Zangemeister-Wittke U., Zupi G., Biroccio A. Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death Differ 2005, 12:1429-1438.
97. Rahman R., Latonen L., Wiman K.G. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene 2005, 24:1320-1327.
98. Masutomi K., Possemato R., Wong J.M., Currier J.L., Tothova Z., Manola J.B., Ganesan S., Lansdorp P.M., Collins K., Hahn W.C. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 2005, 102:8222-8227.
99. Lim K.W., Lacroix L., Yue D.J., Lim J.K., Lim J.M., Phan A.T. Coexistence of two distinct G-quadruplex conformations in the hTERT promoter. J Am Chem Soc 2010, 132:12331-12342.
100. Grand C.L., Han H., Munoz R.M., Weitman S., Von Hoff D.D., Hurley L.H., Bearss D.J. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002, 1:565-573.
101. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
102. Patton E.E., Harrington L. Cancer: trouble upstream. Nature 2013, 495:320-321.
103. Lee T.I., Young R.A. Transcriptional regulation and its misregulation in disease. Cell 2013, 152:1237-1251.
104. Armanios M., Price C. Telomeres and disease: an overview. Mutat Res 2012, 730:1-2.
105. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J Clin Invest 2013, 123:996-1002.
106. Ruden M., Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013, 39:444-456.
107. Sullivan R.J., Flaherty K.T. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013, 49:1297-1304.